CompletedNCT00001393
Genetic Markers for Focal Segmental Glomerulosclerosis
Studying Nephrotic syndrome without extrarenal manifestations
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Principal Investigator
- Anirban Ganguli, M.D.National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Enrollment
- 616 enrolled
- Eligibility
- All sexes
- Timeline
- 1996
Study locations (1)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00001393 on ClinicalTrials.govOther trials for Nephrotic syndrome without extrarenal manifestations
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07267026A Study to Evaluate the Safety, Tolerability and PK of SK-09Consun Pharmaceutical Group
- RECRUITINGPHASE4NCT07219121Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental GlomerulosclerosisTravere Therapeutics, Inc.
- RECRUITINGNANCT06867471Effects of Exogenous Ketosis on Proteinuria and Renal FunctionGødstrup Hospital
- RECRUITINGPHASE3NCT05716880Ketoanalogues for Muscle Mass Loss in Nephrotic SyndromeMilitary Institute od Medicine National Research Institute
- RECRUITINGPHASE2NCT05003986Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular DiseasesTravere Therapeutics, Inc.
- RECRUITINGNCT01209000Nephrotic Syndrome Study NetworkUniversity of Michigan
- RECRUITINGNCT01094327Proteinuria in Pre and Post TransplantUniversity of Miami
See all trials for Nephrotic syndrome without extrarenal manifestations →